Ph3 Infigratinib UC w/ FGFR3 Alt

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Disease Types: Bladder,&nbs

Available at: {clinical_trial_location backspace="7"}Ph3 Infigratinib UC w/ FGFR3 Alt, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}